USP22-depleted tumor cells exhibited a high sensitivity to HSP90 inhibitor ganetespib, suggesting that targeting USP22 and HSP90β may prove effective for the treatment of breast and colorectal cancer (55). Here, HSP90AB1 is linked to neoplasm.